Toxicity Management of Systemic Kidney Cancer Therapies.
Adverse events
Immune-related adverse events
Renal cell carcinoma
Toxicity management
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
18
9
2023
pubmed:
24
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
Systemic treatments for metastatic renal cell carcinoma have expanded to include antiangiogenic agents targeting either vascular endothelial growth factor receptor, immune checkpoint inhibitors against cytotoxic T-lymphocyte antigen 4, or programmed cell death 1 pathways, and combinations of these treatments. The hypoxia inducible factor-2 inhibitors are emerging, whereas mammalian target of rapamycin (inhibitors) role is fading. To sustain optimal efficacy of these agents, potential toxicities must be recognized early and clinically managed. Here, the authors discuss the adverse events attributable to these treatments and management strategies.
Identifiants
pubmed: 37353375
pii: S0889-8588(23)00061-8
doi: 10.1016/j.hoc.2023.05.006
pii:
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
993-1003Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.